Movatterモバイル変換

[0]ホーム
URL:

US20050124604A1 - Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases - Google Patents

Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseasesDownload PDF

Info

Publication number
US20050124604A1
US20050124604A1US10/920,031US92003104AUS2005124604A1US 20050124604 A1US20050124604 A1US 20050124604A1US 92003104 AUS92003104 AUS 92003104AUS 2005124604 A1US2005124604 A1US 2005124604A1
Authority
US
United States
Prior art keywords
substituted
compound
group
hydrogen
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/920,031
Inventor
Jagadish Sircar
Sunil K.C.
Wenbin Ying
Timothy Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avanir Pharmaceuticals Inc
Original Assignee
Avanir Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=34272569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20050124604(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Avanir Pharmaceuticals IncfiledCriticalAvanir Pharmaceuticals Inc
Priority to US10/920,031priorityCriticalpatent/US20050124604A1/en
Assigned to AVANIR PHARMACEUTICALS, INC.reassignmentAVANIR PHARMACEUTICALS, INC.ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: DAVIS, TIMOTHY JAMES, KUMAR K. C., SUNIL, SIRCAR, JAGADISH, YING, WENBIN
Publication of US20050124604A1publicationCriticalpatent/US20050124604A1/en
Priority to US11/687,601prioritypatent/US7361760B2/en
Abandonedlegal-statusCriticalCurrent

Links

Classifications

Definitions

Landscapes

Abstract

Inhibitors of MIF having a naphthyridine backbone are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures:
Figure US20050124604A1-20050609-C00001

including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R, R1, R2, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

Description

Claims (71)

Figure US20050124604A1-20050609-C00760
or a stereoisomer, a prodrug, or a pharmaceutically acceptable salt thereof, wherein:
R is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, acylalkyl, subtituted acylalkyl, heterocycle, substituted heterocycle, —(CH2)mC(═O)Ar, and —(CH2)mNR4R5;
R1is selected from the group consisting of —CN, —NO, —NO2, —C(═O)R3, —C(═O)OH, —NHC(═O)R3, —C(═O)OR3, —C(═O)NR4R5, —NR3C(═O)R3, —SO2NR4R5, —NR3SO2R3, —NHSO2R3, —S(O)mR3, —(CH2)mNR4R5, and —(CH2)mC(═O)Ar;
R2is selected from the group consisting —CH2R3, —NR4R5, —OR3, and —R3;
R3is independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, acylalkyl, subtituted acylalkyl, heterocycle, substituted heterocycle;
R4and R5are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, acylalkyl, subtituted acylalkyl, heterocycle, and substituted heterocycle, or R4and R5taken together comprise heterocycle or substituted heterocycle;
X is selected from the group consisting of hydrogen, halogen, —F, —Cl, —CN, —NO, —NO2, —OCF3, —CF3, —NHSO2R3, —C(═O)R3, —C(═O)OR3, —C(═O)NR4R5, —NR3C(═O)R3, —NR3SO2R3, —S(O)mR3, —R3, —OR3, —SR3, —C(═O)OH, —NHC(═O)R3, and —NR4R5;
Y is selected from the group consisting of hydrogen, halogen, —F, —Cl, —CN, —NO, —NO2, —OCF3, —CF3, —NHSO2R3, —C(═O)R3, —C(═O)OR3, —C(═O)NR4R5, —NR3C(═O)R3, —NR3SO2R3, —S(O)mR3, —R3, —OR3, —SR3, —C(═O)OH, —NHC(═O)R3, and —NR4R5;
Z is selected from the group consisting of hydrogen, halogen, —F, l, —CN, —NO, —NO2, —OCF3, —CF3, —NHSO2R3, —C(═O)R3, —C(═O)OR3, —C(═O)NR4R5, —NR3C(═O)R3, —NR3SO2R3, —S(O)mR3, —R3, —OR3, —SR3, —C(═O)OH, —NHC(═O)R3, and —NR4R5;
Ar is selected from the group consisting of aryl and substituted aryl;
m is independently 0, 1, 2, 3, or 4; and
n is 0, 1, or 2.
Figure US20050124604A1-20050609-C00761
or a stereoisomer, a prodrug, or a pharmaceutically acceptable salt thereof, wherein:
R is selected from the group consisting of hydrogen, C1-C12alkyl, C2-C12alkenyl, C3-C12cycloalkyl, C6-C12aryl, C7-C12arylalkyl, C7-C12alkylaryl, C2-C12acylalkyl, C3-C12heterocyclealkyl, C3-C12alkylheterocycle, and C2-C12heterocycle, wherein R is substituted with one or more substituents selected from the group consisting of hydrogen, —F, —Cl, —CN, —NO, —NO2, —C(═O)R3, —C(═O)OR3, —OC(═O)R3, —C(═O)NR3R3, —NR3C(═O)R3, —SO2NR3R3, —NR3SO2R3, —OR3, —SR3, —NHSO2R3, —S(O)mR3, —C(═O)OH, —NHC(═O)R3, —(CH2)mC(═O)Ar, and —(CH2)mNR3R3;
R1is selected from the group consisting of —CN, —NO, —NO2, —C(═O)R3, —C(═O)OR3, —OC(═O)R3, —C(═O)NR3R3, —NR3C(═O)R3, —SO2NR3R3, —NR3SO2R3, —OR3, —SR3, —NHSO2R3, —S(O)mR3, —C(═O)OH, —NHC(═O)R3, —(CH2)mC(═O)Ar, and —(CH2)mNR3R3;
R2is selected from the group consisting —NR4R5, —OR3, and —R3;
R3is independently selected from the group consisting of C1-C12alkyl, C2-C12alkenyl, C3-C12cycloalkyl, C6-C12aryl, C7-C12arylalkyl, C7-C12alkylaryl, C2-C12acylalkyl, C3-C12heterocyclealkyl, C3-C12alkylheterocycle, and C2-C12heterocycle, wherein R3is substituted with one or more substituents selected from the group consisting of hydrogen, —F, —Cl, —CN, —NO, —NO2, —CN, —NO, —NO2, C1-C12alkoxy, and C1-C12alkylthio;
R4and R5are independently selected from the group consisting C1-C12alkyl, C2-C12alkenyl, C3-C12cycloalkyl, C6-C12aryl, C7-C12arylalkyl, C7-C12alkylaryl, C2-C12acylalkyl, C3-C12heterocyclealkyl, C3-C12alkylheterocycle, and C2-C12heterocycle substituted with one or more substituents selected from the group consisting of hydrogen, —F, —Cl, —CN, —NO, —NO2, —CN, —NO, —NO2, C1-C12alkoxy, and C1-C12alkylthio, or R4and R5together comprise a C2-C12heterocycle substituted with one or more substituents selected from the group consisting of hydrogen, —F, —Cl, —CN, —NO, —NO2, —CN, —NO, —NO2, —OCF3, —CF3, C1-C12alkoxy, and C1-C12alkylthio;
X is selected from the group consisting of hydrogen, —F, —Cl, —CN, —NO, —NO2, —OCF3, —CF3, —NHSO2R3, —C(═O)R3, —C(═O)OR3, —OC(═O)R3, —C(═O)NR3R3, —NR3C(═O)R3, —SO2NR3R3, —NR3SO2R3, —OR3, —S(O)mR3, —SR3, —C(═O)OH, —NHC(═O)R3, —(CH2)mC(═O)Ar, and —(CH2)mNR3R3;
Y is selected from the group consisting of hydrogen, —F, —Cl, —CN, —NO, —NO2, —OCF3, —CF3, —NHSO2R3, —C(═O)R3, —C(═O)OR3, —OC(═O)R3, —C(═O)NR3R3, —NR3C(═O)R3, —SO2NR3R3, —NR3SO2R3, —OR3, —S(O)mR3, —SR3, —C(═O)OH, —NHC(═O)R3, —(CH2)mC(═O)Ar, and —(CH2)mNR3R3;
Z is selected from the group consisting of hydrogen, —F, —Cl, —CN, —NO, —NO2, —OCF3, —CF3, —NHSO2R3, —C(═O)R3, —C(═O)OR3, —OC(═O)R3, —C(═O)NR3R3, —NR3C(═O)R3, —SO2NR3R3, —NR3SO2R3, —OR3, —S(O)mR3, —SR3, —C(═O)OH, —NHC(═O)R3, —(CH2)mC(═O)Ar, and —(CH2)mNR3R3;
Ar is independently selected from the group consisting of C6-C12aryl substituted with one or more substituents selected from the group consisting of hydrogen, —F, —Cl, —CN, —NO, —NO2, —CN, —NO, —NO2, C1-C12alkyl, C1-C12alkoxy, and C1-C12alkylthio; and
m is independently 0, 1, 2, 3, or 4.
Figure US20050124604A1-20050609-C00762
or a stereoisomer, a prodrug, or a pharmaceutically acceptable salt thereof, wherein:
R is selected from the group consisting of hydrogen, C1-C12alkyl, C2-C12alkenyl, C3-C12cycloalkyl, C6-C12aryl, C7-C12arylalkyl, C7-C12alkylaryl, C2-C12acylalkyl, C3-C12heterocyclealkyl, C3-C12alkylheterocycle, and C2-C12heterocycle, wherein R is substituted with one or more substituents selected from the group consisting of hydrogen, —F, —Cl, —CN, —NO, —NO2, —NHSO2R3, —C(═O)R3, —C(═O)OR3, —OC(═O)R3, —C(═O)NR3R3, —NR3C(═O)R3, —SO2NR3R3, —NR3SO2R3, —OR3, —SR3, —S(O)mR3, —(CH2)mC(═O)Ar, and —(CH2)mNR3R3;
R1is selected from the group consisting of —CN, —NO, —NO2, —C(═O)R3, —C(═O)OR3, —OC(═O)R3, —NHSO2R3, —C(═O)NR3R3, —NR3C(═O)R3, —SO2NR3R3, —NR3SO2R3, —OR3, —SR3, —S(O)mR3, —(CH2)mC(═O)Ar, and CH2)mNR3R3;
R2is selected from the group consisting —NR4R5, —OR3, and —R3;
R3is independently selected from the group consisting of C1-C12alkyl, C2-C12alkenyl, C3-C12cycloalkyl, C6-C12aryl, C7-C12arylalkyl, C7-C12alkylaryl, C2-C12acylalkyl, C3-C12heterocyclealkyl, C3-C12alkylheterocycle, and C2-C12heterocycle, wherein R3is substituted with one or more substituents selected from the group consisting of hydrogen, —F, —Cl, —CN, —NO, —NO2, —CN, —NO, —NO2, C1-C12alkoxy, and C1-C12alkylthio;
R4and R5are independently selected from the group consisting C1-C12alkyl, C2-C12alkenyl, C3-C12cycloalkyl, C6-C12aryl, C7-C12arylalkyl, C7-C12alkylaryl, C2-C12acylalkyl, C3-C12heterocyclealkyl, C3-C12alkylheterocycle, and C2-C12heterocycle substituted with one or more substituents selected from the group consisting of hydrogen, —F, —Cl, —CN, —NO, —NO2, —CN, —NO, —NO2, C1-C12alkoxy, and C1-C12alkylthio, or R4and R5together comprise a C2-C12heterocycle substituted with one or more substituents selected from the group consisting of hydrogen, —F, —Cl, —CN, —NO, —NO2, —CN, —NO, —NO2, C1-C12alkyl, C1-C12alkoxy, C1-C12alkylthio, and C1-C12alkyl substituted with one or more substituents selected from the group consisting of hydrogen, —F, and —Cl;
X is selected from the group consisting of hydrogen, —F, —Cl, —OCF3, —CF3, C1-C12alkyl, and C1-C12alkyl substituted with one or more substituents selected from the group consisting of hydrogen, —F, and —Cl;
Y is selected from the group consisting of hydrogen, —F, —Cl, —OCF3, —CF3, C1-C12alkyl, and C1-C12alkyl substituted with one or more substituents selected from the group consisting of hydrogen, —F, and —Cl;
Z is selected from the group consisting of hydrogen, —F, —Cl, —OCF3, —CF3, C1-C12alkyl, and C1-C12alkyl substituted with one or more substituents selected from the group consisting of hydrogen, —F, and —Cl;
Ar is selected from the group consisting of C6-C12aryl substituted with one or more substituents selected from the group consisting of hydrogen, —F, —Cl, C1-C12alkyl, and C1-C12alkyl substituted with one or more substituents selected from the group consisting of hydrogen, —F, and —Cl; and
m is independently 0, 1, 2, 3, or 4.
66. A process for preparing a compound ofclaim 1, the process comprising the steps of:
reacting POCl3with a compound of Formula (3):
Figure US20050124604A1-20050609-C00800
wherein R is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, acylalkyl, subtituted acylalkyl, heterocycle, substituted heterocycle, —(CH2)mC(═O)Ar, and CH2)mNR4R5; R1is selected from the group consisting of —CN, —NO, —NO2, —C(═O)R3, —C(═O)OH, —NHC(═O)R3, —C (═O)OR3, —C(═O)NR4R5, —NR3C(═O)R3, —SO2NR4R5, —NR3SO2R3, —NHSO2R3, —S(O)mR3, —(CH2)mNR4R5, and CH2)mC(═O)Ar; R3is independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, acylalkyl, subtituted acylalkyl, heterocycle, substituted heterocycle; R4and R5are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, acylalkyl, subtituted acylalkyl, heterocycle, and substituted heterocycle, or R4and R5taken together comprise heterocycle or substituted heterocycle; X is selected from the group consisting of hydrogen, halogen, —F, —Cl, —CN, —NO, —NO2, —OCF3, —CF3, —NHSO2R3, —C(═O)R3, —C(═O)OR3, —C(═O)NR4R5, —NR3C(═O)R3, —NR3SO2R3, —S(O)mR3, —R3, —OR3, —SR3, —C(═O)OH, —NHC(═O)R3, and —NR4R5; Y is selected from the group consisting of hydrogen, halogen, —F, —Cl, —CN, —NO, —NO2, —OCF3, —CF3, —NHSO2R3, —C(═O)R3, —C(═O)OR3, —C(═O)NR4R5, —NR3C(═O)R3, —NR3SO2R3, —S(O)mR3, —R3, —OR3, —SR3, —C(═O)OH, —NHC(═O)R3, and —NR4R5; Z is selected from the group consisting of hydrogen, halogen, —F, —Cl, N, —NO, —NO2, —OCF3, —CF3, —NHSO2R3, —C(═O)R3, C(═O)OR3, —C(═O)NR5, —NR3C(═O)R3, —NR3SO2R3, —S(O)mR3, —R3, —OR3, —SR3, —C(═O)OH, —NHC(═O)R3, and —NR4R5; Ar is selected from the group consisting of aryl and substituted aryl; and m is independently 0, 1, 2, 3, or 4; thereby yielding a compound of Formula (4):
Figure US20050124604A1-20050609-C00801
Figure US20050124604A1-20050609-C00802
Figure US20050124604A1-20050609-C00803
77. A process for preparing a compound ofclaim 1, the process comprising the steps of:
reacting a compound of Formula (13):
Figure US20050124604A1-20050609-C00804
wherein R is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, acylalkyl, subtituted acylalkyl, heterocycle, substituted heterocycle, —(CH2)mC(═O)Ar, and —(CH2)mNR4R5; R4and R5are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, acylalkyl, subtituted acylalkyl, heterocycle, and substituted heterocycle, or R4and R5taken together comprise heterocycle or substituted heterocycle; X is selected from the group consisting of hydrogen, halogen, —F, —Cl, —CN, —NO, —NO2, —OCF3, —CF3, —NHSO2R3, —C(═O)R3, —C(═O)OR3, —C(═O)NR4R5, —NR3C(═O)R3, —NR3SO2R3, —S(O)mR3, —R3, —OR3, —SR3, —C(═O)OH, —NHC(═O)R3, and —NR4R5; Y is selected from the group consisting of hydrogen, halogen, —F, —Cl, —CN, —NO, —NO2, —OCF3, —CF3, —NHSO2R3, —C(═O)R3, —C(═O)OR3, —C(═O)NR4R5, —NR3C(═O)R3, —NR3SO2R3, —S(O)mR3, —R3, —OR3, —SR3, —C(═O)OH, —NHC(═O)R3, and —NR4R5; Z is selected from the group consisting of hydrogen, halogen, —F, —Cl, —CN, —NO, —NO2, —OCF3, —CF3, —NHSO2R3, —C(═O)R3, —C(═O)OR3, —C(═O)NR4R5, —NR3C(═O)R3, —NR3SO2R3, —S(O)mR3, —R3, —OR3, —SR3, —C(═O)OH, —NHC(═O)R3, and —NR4R5; R3is independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, acylalkyl, subtituted acylalkyl, heterocycle, substituted heterocycle; Ar is selected from the group consisting of aryl and substituted aryl; and m is independently 0, 1, 2, 3, or 4, with cyclohexylamine, thereby yielding a compound of Formula (14):
Figure US20050124604A1-20050609-C00805
Figure US20050124604A1-20050609-C00806
Figure US20050124604A1-20050609-C00807
Figure US20050124604A1-20050609-C00808
82. A process for preparing a compound ofclaim 1, the process comprising the steps of:
reacting a compound of Formula (23):
Figure US20050124604A1-20050609-C00809
wherein R1is selected from the group consisting of —CN, —NO, —NO2, —C(═O)R3, —C(═O)OH, —NHC(═O)R3, —C(═O)OR3, —C(═O)NR4R5, —NR3C(═O)R3, —SO2NR4R5, —NR3SO2R3, —NHSO2R3, —S(O)mR3, —(CH2)mNR4R5, and —(CH2)mC(═O)Ar; R3is independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, acylalkyl, subtituted acylalkyl, heterocycle, substituted heterocycle; R4and R5are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, acylalkyl, subtituted acylalkyl, heterocycle, and substituted heterocycle, or R4and R5taken together comprise heterocycle or substituted heterocycle; X is selected from the group consisting of hydrogen, halogen, —F, —Cl, —CN, —NO, —NO2, —OCF3, —CF3, —NHSO2R3, —C(═O)R3, —C(═O)OR3, —C(═O)NR4R5, —NR3C(═O)R3, —NR3SO2R3, —S(O)mR3, —R3, —OR3, —SR3, —C(═O)OH, —NHC(═O)R3, and —NR4R5; Y is selected from the group consisting of hydrogen, halogen, —F, —Cl, —CN, —NO, —NO2, —OCF3, —CF3, —NHSO2R3, —C(═O)R3, —C(═O)OR3, —C(═O)NR4R5, —NR3C(═O)R3, —NR3SO2R3, —S(O)mR3, —R3, —OR3, —SR3, —C(═O)OH, —NHC(═O)R3, and —NR4R5; Z is selected from the group consisting of hydrogen, halogen, —F, —Cl, —CN, —NO, —NO2, —OCF3, —CF3, —NHSO2R3, —C(═O)R3, —C(═O)OR3, —C(═O)NR4R5, —NR3C(═O)R3, —NR3SO2R3, —S(O)mR3, —R3, —OR3, —SR3, —C(═O)OH, —NHC(═O)R3, and —NR4R5; Ar is independently selected from the group consisting of aryl and substituted aryl; and m is independently 0, 1, 2, 3, or 4, with POCl3and trifluoroacetic acid, thereby yielding a compound of Formula (24):
Figure US20050124604A1-20050609-C00810
Figure US20050124604A1-20050609-C00811
Figure US20050124604A1-20050609-C00812
Figure US20050124604A1-20050609-C00813
US10/920,0312003-08-222004-08-17Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseasesAbandonedUS20050124604A1 (en)

Priority Applications (2)

Application NumberPriority DateFiling DateTitle
US10/920,031US20050124604A1 (en)2003-08-222004-08-17Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
US11/687,601US7361760B2 (en)2003-08-222007-03-16Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US49744303P2003-08-222003-08-22
US10/920,031US20050124604A1 (en)2003-08-222004-08-17Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases

Related Child Applications (1)

Application NumberTitlePriority DateFiling Date
US11/687,601ContinuationUS7361760B2 (en)2003-08-222007-03-16Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases

Publications (1)

Publication NumberPublication Date
US20050124604A1true US20050124604A1 (en)2005-06-09

Family

ID=34272569

Family Applications (2)

Application NumberTitlePriority DateFiling Date
US10/920,031AbandonedUS20050124604A1 (en)2003-08-222004-08-17Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
US11/687,601Expired - Fee RelatedUS7361760B2 (en)2003-08-222007-03-16Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases

Family Applications After (1)

Application NumberTitlePriority DateFiling Date
US11/687,601Expired - Fee RelatedUS7361760B2 (en)2003-08-222007-03-16Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases

Country Status (13)

CountryLink
US (2)US20050124604A1 (en)
EP (1)EP1656376A1 (en)
JP (1)JP2007503388A (en)
CN (1)CN1839133A (en)
AR (1)AR045471A1 (en)
AU (1)AU2004268941A1 (en)
BR (1)BRPI0413695A (en)
CA (1)CA2531506A1 (en)
MX (1)MXJL06000006A (en)
PE (1)PE20051112A1 (en)
TW (1)TW200524928A (en)
UY (1)UY28483A1 (en)
WO (1)WO2005021546A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20040204586A1 (en)*2003-02-142004-10-14Jagadish SircarInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20050282236A1 (en)*2001-05-242005-12-22Gaeta Federico CInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20060229314A1 (en)*2005-03-242006-10-12Jagadish SircarThienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
WO2007109251A3 (en)*2006-03-212007-12-13Avanir PharmaceuticalsTumor necrosis factor alpha inhibitors and their use in the treatment of human diseases
US20110105497A1 (en)*2009-10-262011-05-05Anantha SudhakarCompounds and methods for treatment of cancer
WO2020006018A1 (en)*2018-06-272020-01-02Bristol-Myers Squibb CompanySubstituted naphthyridinone compounds useful as t cell activators
WO2020006016A1 (en)*2018-06-272020-01-02Bristol-Myers Squibb CompanyNaphthyridinone compounds useful as t cell activators
WO2022093817A1 (en)*2020-10-262022-05-05Yale UniversityMacrophage migration inhibitory factor inhibitors, and methods of making and using same
US11584747B2 (en)2019-08-282023-02-21Bristol-Myers Squibb CompanySubstituted pyridopyrimidinonyl compounds useful as T cell activators
US11767321B2 (en)2020-10-052023-09-26Enliven Inc.5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases
US11964973B2 (en)2019-12-232024-04-23Bristol-Myers Squibb CompanySubstituted bicyclic compounds useful as T cell activators

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP2097416B1 (en)2006-12-182012-09-12Amgen, IncAzaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
EP2111399A2 (en)2006-12-182009-10-28Amgen Inc.Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
ES2446418T3 (en)2007-04-182014-03-07Amgen, Inc Indanone derivatives that inhibit prolyl hydroxylase
ES2442847T3 (en)2007-04-182014-02-13Amgen, Inc Quinolones and azaquinolones that inhibit prolyl hydroxylase
ES2389063T3 (en)2007-05-042012-10-22Amgen, Inc Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
US8097620B2 (en)2007-05-042012-01-17Amgen Inc.Diazaquinolones that inhibit prolyl hydroxylase activity
US9643922B2 (en)2008-08-182017-05-09Yale UniversityMIF modulators
US9540322B2 (en)2008-08-182017-01-10Yale UniversityMIF modulators
EP2592933B1 (en)*2010-07-162017-04-05Anderson GawecoMif inhibitors and their uses
US9238643B2 (en)2010-09-062016-01-19Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of SciencesAmide compounds
WO2012142498A2 (en)*2011-04-132012-10-18Innovimmune Biotherapeutics, Inc.Mif inhibitors and their uses
CN103360388B (en)*2012-04-102017-11-14江苏先声药业有限公司The 7-naphthyridine derivatives of 5 amino Isosorbide-5-Nitrae dihydro 1,8 and its pharmaceutical composition and purposes
WO2015095052A1 (en)2013-12-172015-06-25Controlled Chemicals, Inc.Isoindolin-1-ones as macrophage migration inhibitory factor (mif) inhibitors
CN116606261A (en)2016-12-222023-08-18美国安进公司KRAS G12C inhibitors and methods of use thereof
JOP20190272A1 (en)2017-05-222019-11-21Amgen IncKras g12c inhibitors and methods of using the same
CA3075046A1 (en)2017-09-082019-03-14Amgen Inc.Inhibitors of kras g12c and methods of using the same
CN107556309B (en)*2017-09-112020-12-01浙江永宁药业股份有限公司Pharmaceutical application of polysubstituted tetrahydronaphthyridine compound and preparation method thereof
AU2019262599B2 (en)2018-05-042023-10-12Amgen Inc.KRAS G12C inhibitors and methods of using the same
MX2020010836A (en)2018-05-042021-01-08Amgen IncKras g12c inhibitors and methods of using the same.
MA52564A (en)2018-05-102021-03-17Amgen Inc KRAS G12C INHIBITORS FOR CANCER TREATMENT
MX2020012731A (en)2018-06-012021-02-22Amgen IncKras g12c inhibitors and methods of using the same.
WO2019241157A1 (en)*2018-06-112019-12-19Amgen Inc.Kras g12c inhibitors for treating cancer
JP7369719B2 (en)2018-06-122023-10-26アムジエン・インコーポレーテツド KRas G12C inhibitors and methods of using the same
JP7516029B2 (en)2018-11-162024-07-16アムジエン・インコーポレーテツド Improved synthesis of key intermediates for KRAS G12C inhibitor compounds
JP7377679B2 (en)2018-11-192023-11-10アムジエン・インコーポレーテツド Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer
WO2020106640A1 (en)2018-11-192020-05-28Amgen Inc.Kras g12c inhibitors and methods of using the same
CN111471059B (en)*2019-01-232022-12-02药捷安康(南京)科技股份有限公司PDE9 inhibitors and uses thereof
EP3939588A4 (en)*2019-03-082023-01-11Transthera Sciences (Nanjing), Inc. USES OF PHOSPHODIESTERASE INHIBITORS
EP3738593A1 (en)2019-05-142020-11-18Amgen, IncDosing of kras inhibitor for treatment of cancers
UA129871C2 (en)2019-05-212025-08-27Емджен Інк. SOLID FORMS

Citations (28)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4284768A (en)*1980-07-021981-08-18American Home Products Corporation1,2-Dihydro-4-amino-2-oxo-3-quinoline-carboxylic acid derivatives
US4299814A (en)*1979-05-251981-11-10Monsanto CompanyRadioimmunoassay of MIF
US4683202A (en)*1985-03-281987-07-28Cetus CorporationProcess for amplifying nucleic acid sequences
US4708937A (en)*1984-10-151987-11-24Brigham & Women's HospitalPurified migration inhibitory factor also having colony stimulating factor activity
US5246869A (en)*1989-03-221993-09-21Wallac OyMethod for the simultaneous assay of ligands
US5328990A (en)*1991-04-261994-07-12The United States Of America As Represented By The Department Of Health And Human ServicesIsolation of macrophage migration inhibition factor from ocular lens
US5350687A (en)*1986-10-031994-09-27Ciba-Geigy CorporationAntibodies which bind to novel lymphokine related peptides
US5352660A (en)*1991-10-311994-10-04Mount Sinai Hospital CorporationMethod for assaying for a substance that affects a SH2-phosphorylated ligand regulatory system
US5411882A (en)*1989-07-051995-05-02Ciba-Geigy CorporationCytokine which mediates inflammation
US5530101A (en)*1988-12-281996-06-25Protein Design Labs, Inc.Humanized immunoglobulins
US5597708A (en)*1984-02-221997-01-28Burroughs Wellcome CompanyCloning of a malarial gene
US5650295A (en)*1995-06-021997-07-22Human Genone Sciences, Inc.Macrophage migration inhibitory factor-3
US5656596A (en)*1986-02-041997-08-12Incyte Pharmaceuticals, Inc.Method of treating lesions in a nervous system
US5683887A (en)*1991-12-201997-11-04The Rockefeller UniversityImmunochemical detection of in vivo advanced glycosylation endproducts
US5700447A (en)*1992-05-211997-12-23The Picowder Institute For Medical ResearchMethods and materials for the diagnosis and treatment of conditions such as stroke
US5733933A (en)*1984-03-191998-03-31The Picower Institute For Medical ResearchMethods and materials for the diagnosis and treatment of conditions such as stroke
US5733524A (en)*1984-03-191998-03-31The Picower Institute For Medical ResearchMethods and materials for the diagnosis and treatment of conditions such as stroke
US5780615A (en)*1992-05-211998-07-14The Picower Institute For Medical ResearchGlycosylation of lipids and lipid-containing particles and diagnostic and therapeutic methods and materials derived therefrom
US5801200A (en)*1984-03-191998-09-01The Picower Institute For Medical ResearchMethods and materials for the diagnosis and treatment of conditions such as stroke
US5883224A (en)*1996-04-191999-03-16Cytokine Sciences, Inc.Characterization of transfer factors and methods of use
US6028081A (en)*1997-08-292000-02-22Ssp Co., Ltd.Substituted quinolone derivatives and pharmaceuticals containing the same
US6030615A (en)*1993-05-172000-02-29The Picower Institute For Medical ResearchCombination method for treating diseases caused by cytokine-mediated toxicity
US6214343B1 (en)*1999-05-242001-04-10Ophidian Pharmaceuticals, Inc.Prevention and treatment of necrotizing enterocolitis
US6238874B1 (en)*1998-07-282001-05-29Biometric Imaging, Inc.Cell motility assay
US6413939B1 (en)*1997-10-312002-07-02The Picower Institute For Medical ResearchInducible phosphofructokinase and the Warburg effect
US6420188B1 (en)*1996-02-162002-07-16The Picower Institute For Medical ResearchScreening assay for the identification of inhibitors for macrophage migration inhibitory factor
US20030195194A1 (en)*2001-05-242003-10-16Gaeta Federico C.A.Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US7235546B2 (en)*2003-02-142007-06-26Avanir PharmaceuticalsInhibitors of macrophage migration inhibitory factor and methods for identifying the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4324893A (en)*1979-04-181982-04-13American Home Products Corporation4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
AU592753B2 (en)1984-05-241990-01-25Ciba-Geigy AgLymphokine in pure foem, novel monoclonal antibodies hybridoma cell lines, processes and applications
US6774227B1 (en)1993-05-172004-08-10Cytokine Pharmasciences, Inc.Therapeutic uses of factors which inhibit or neutralize MIF activity
AU692159B2 (en)1993-05-171998-06-04Cytokine Pharmasciences, Inc.Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity
US6492428B1 (en)2000-07-262002-12-10The Picower Institute For Medical ResearchCompounds having MIF antagonist activity
CA2250067A1 (en)1996-04-181997-10-23Ariad Pharmaceuticals, Inc.In vitro fluorescence polarization assay
PT1036192E (en)1997-12-052003-06-30Upjohn Co HIGH-PERFORMANCE RESEARCH ASSAYS BASED ON FLUORESCENCE FOR PROTEIN-KINASES AND PHOSPHATES
AU778042B2 (en)*1999-10-192004-11-11Merck & Co., Inc.Tyrosine kinase inhibitors
JP2003513065A (en)*1999-10-292003-04-08ザ・ピコワー・インスティチュート・フォー・メディカル・リサーチ Compound having MIF antagonist activity
JP2004521892A (en)*2000-12-202004-07-22メルク　エンド　カムパニー　インコーポレーテッド (Halo-benzocarbonyl) heterocyclic fused phenyl p38 kinase inhibitors
JP4117462B2 (en)*2001-07-032008-07-16株式会社大塚製薬工場 Naphthyridine and quinoline derivatives
US6822097B1 (en)*2002-02-072004-11-23Amgen, Inc.Compounds and methods of uses
GB2405146A (en)*2002-06-072005-02-23Cortical Pty LtdNapthalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF)

Patent Citations (35)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4299814A (en)*1979-05-251981-11-10Monsanto CompanyRadioimmunoassay of MIF
US4284768A (en)*1980-07-021981-08-18American Home Products Corporation1,2-Dihydro-4-amino-2-oxo-3-quinoline-carboxylic acid derivatives
US5597708A (en)*1984-02-221997-01-28Burroughs Wellcome CompanyCloning of a malarial gene
US5733524A (en)*1984-03-191998-03-31The Picower Institute For Medical ResearchMethods and materials for the diagnosis and treatment of conditions such as stroke
US5733933A (en)*1984-03-191998-03-31The Picower Institute For Medical ResearchMethods and materials for the diagnosis and treatment of conditions such as stroke
US5801200A (en)*1984-03-191998-09-01The Picower Institute For Medical ResearchMethods and materials for the diagnosis and treatment of conditions such as stroke
US4708937A (en)*1984-10-151987-11-24Brigham & Women's HospitalPurified migration inhibitory factor also having colony stimulating factor activity
US4683202B1 (en)*1985-03-281990-11-27Cetus Corp
US4683202A (en)*1985-03-281987-07-28Cetus CorporationProcess for amplifying nucleic acid sequences
US5656596A (en)*1986-02-041997-08-12Incyte Pharmaceuticals, Inc.Method of treating lesions in a nervous system
US5350687A (en)*1986-10-031994-09-27Ciba-Geigy CorporationAntibodies which bind to novel lymphokine related peptides
US5702920A (en)*1986-10-031997-12-30Novartis CorporationDNAS encoding human macrophage migration inhibition factor related peptides
US5530101A (en)*1988-12-281996-06-25Protein Design Labs, Inc.Humanized immunoglobulins
US5246869A (en)*1989-03-221993-09-21Wallac OyMethod for the simultaneous assay of ligands
US5411882A (en)*1989-07-051995-05-02Ciba-Geigy CorporationCytokine which mediates inflammation
US5821336A (en)*1989-07-051998-10-13Novartis CoporationCytokine which mediates inflammation
US5328990A (en)*1991-04-261994-07-12The United States Of America As Represented By The Department Of Health And Human ServicesIsolation of macrophage migration inhibition factor from ocular lens
US5352660A (en)*1991-10-311994-10-04Mount Sinai Hospital CorporationMethod for assaying for a substance that affects a SH2-phosphorylated ligand regulatory system
US5733546A (en)*1991-12-201998-03-31The Rockefeller UniversityImmunochemical detection of in vivo advanced glycosylation endproducts
US5683887A (en)*1991-12-201997-11-04The Rockefeller UniversityImmunochemical detection of in vivo advanced glycosylation endproducts
US5780615A (en)*1992-05-211998-07-14The Picower Institute For Medical ResearchGlycosylation of lipids and lipid-containing particles and diagnostic and therapeutic methods and materials derived therefrom
US5869534A (en)*1992-05-211999-02-09The Picower Institute For Medical ResearchGlycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US5700447A (en)*1992-05-211997-12-23The Picowder Institute For Medical ResearchMethods and materials for the diagnosis and treatment of conditions such as stroke
US6030615A (en)*1993-05-172000-02-29The Picower Institute For Medical ResearchCombination method for treating diseases caused by cytokine-mediated toxicity
US6080407A (en)*1993-05-172000-06-27The Picower Institute For Medical ResearchDiagnostic assays for MIF
US5986060A (en)*1994-05-161999-11-16Human Genome Sciences, Inc.Macrophage Migration Inhibitory Factor-3
US5650295A (en)*1995-06-021997-07-22Human Genone Sciences, Inc.Macrophage migration inhibitory factor-3
US6420188B1 (en)*1996-02-162002-07-16The Picower Institute For Medical ResearchScreening assay for the identification of inhibitors for macrophage migration inhibitory factor
US5883224A (en)*1996-04-191999-03-16Cytokine Sciences, Inc.Characterization of transfer factors and methods of use
US6028081A (en)*1997-08-292000-02-22Ssp Co., Ltd.Substituted quinolone derivatives and pharmaceuticals containing the same
US6413939B1 (en)*1997-10-312002-07-02The Picower Institute For Medical ResearchInducible phosphofructokinase and the Warburg effect
US6238874B1 (en)*1998-07-282001-05-29Biometric Imaging, Inc.Cell motility assay
US6214343B1 (en)*1999-05-242001-04-10Ophidian Pharmaceuticals, Inc.Prevention and treatment of necrotizing enterocolitis
US20030195194A1 (en)*2001-05-242003-10-16Gaeta Federico C.A.Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US7235546B2 (en)*2003-02-142007-06-26Avanir PharmaceuticalsInhibitors of macrophage migration inhibitory factor and methods for identifying the same

Cited By (61)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20070197547A1 (en)*2001-05-242007-08-23Avanir PharmaceuticalsInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20060094727A1 (en)*2001-05-242006-05-04Gaeta Federico CInhibitors of macrophase migration inhibitory factor and methods for identifying the same
US7084141B2 (en)2001-05-242006-08-01Avanir PharmaceuticalsInhibitors of macrophase migration inhibitory factor and methods for identifying the same
US20060194793A1 (en)*2001-05-242006-08-31Gaeta Federico CInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20060194792A1 (en)*2001-05-242006-08-31Gaeta Federico CInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20060194818A1 (en)*2001-05-242006-08-31Gaeta Federico CInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20060199825A1 (en)*2001-05-242006-09-07Gaeta Federico CInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20060199827A1 (en)*2001-05-242006-09-07Gaeta Federico CInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20060205734A1 (en)*2001-05-242006-09-14Gaeta Federico CInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20060235023A1 (en)*2001-05-242006-10-19Gaeta Federice CInhibitors of macrophage migration inhibitory factor and methods for indentifying the same
US7129236B2 (en)2001-05-242006-10-31Avanir PharmaceuticalsInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US7157469B2 (en)2001-05-242007-01-02Avanir PharmaceuticalsInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20070021440A1 (en)*2001-05-242007-01-25Gaeta Federico CInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US7192955B2 (en)2001-05-242007-03-20Avanir PharmaceuticalsInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US7192961B2 (en)2001-05-242007-03-20Avanir PharmaceuticalsInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US7732146B2 (en)2001-05-242010-06-08Avanir PharmaceuticalsMethod for screening an agent that modulates activity of macrophage migration inhibitory factor
US7514225B2 (en)2001-05-242009-04-07Avanir PharmaceuticalsMethod for screening an agent that modulates activity of macrophage migration inhibitory factor
US7202248B2 (en)2001-05-242007-04-10Avanir PharmaceuticalsInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US7230106B2 (en)2001-05-242007-06-12Avanir PharmaceuticalsProcess for the preparation of inhibitors of macrophage migration inhibitory factor
US7435737B2 (en)2001-05-242008-10-14Avanir PharmaceutialsInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US7432374B2 (en)2001-05-242008-10-07Avanir PharmaceuticalsInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20050282236A1 (en)*2001-05-242005-12-22Gaeta Federico CInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US7235565B2 (en)2001-05-242007-06-26Avanir PharmaceuticalsInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US7238809B2 (en)2001-05-242007-07-03Avanir PharmaceuticalsProcess for the preparation of inhibitors of macrophage migration inhibitory factor
US20070232613A1 (en)*2001-05-242007-10-04Gaeta Federico CInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20070270395A1 (en)*2003-02-142007-11-22Avanir PharmaceuticalsInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20070054923A1 (en)*2003-02-142007-03-08Jagadish SircarInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20040204586A1 (en)*2003-02-142004-10-14Jagadish SircarInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20070179132A1 (en)*2003-02-142007-08-02Avanir PharmaceuticalsInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20070238736A9 (en)*2003-02-142007-10-11Jagadish SircarInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US7235546B2 (en)2003-02-142007-06-26Avanir PharmaceuticalsInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20070054898A1 (en)*2003-02-142007-03-08Jagadish SircarInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US7312220B2 (en)2003-02-142007-12-25Avanir PharmaceuticalsInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US7312221B2 (en)2003-02-142007-12-25Avanir PharmaceuticalsInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20070054920A1 (en)*2003-02-142007-03-08Jagadish SircarInhibitors of macrophage migration inhibitory factor and methods for identifying the same
US7365200B2 (en)2005-03-242008-04-29Avanir PharmaceuticalsThienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
US20070179149A1 (en)*2005-03-242007-08-02Avanir PharmaceuticalsThienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
US20060229314A1 (en)*2005-03-242006-10-12Jagadish SircarThienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
US20080139551A1 (en)*2006-03-212008-06-12Avanir PharmaceuticalsTumor necrosis factor alpha inhibitors and their use in the treatment of human diseases
WO2007109251A3 (en)*2006-03-212007-12-13Avanir PharmaceuticalsTumor necrosis factor alpha inhibitors and their use in the treatment of human diseases
US20110105497A1 (en)*2009-10-262011-05-05Anantha SudhakarCompounds and methods for treatment of cancer
US8470817B2 (en)2009-10-262013-06-25Sunesis Pharmaceuticals, Inc.Compounds and methods for treatment of cancer
WO2020006018A1 (en)*2018-06-272020-01-02Bristol-Myers Squibb CompanySubstituted naphthyridinone compounds useful as t cell activators
AU2019291792B2 (en)*2018-06-272022-09-29Bristol-Myers Squibb CompanyNaphthyridinone compounds useful as T cell activators
US10669272B2 (en)2018-06-272020-06-02Bristol-Myers Squibb CompanySubstituted naphthyridinone compounds useful as T cell activators
KR20210024587A (en)*2018-06-272021-03-05브리스톨-마이어스 스큅 컴퍼니 Naphthyridinone compounds useful as T cell activators
KR20210024586A (en)*2018-06-272021-03-05브리스톨-마이어스 스큅 컴퍼니 Substituted naphthyridinone compounds useful as T cell activators
US10954238B1 (en)2018-06-272021-03-23Bristol-Myers Squibb CompanySubstituted naphthyridinone compounds useful as T cell activators
CN112585139A (en)*2018-06-272021-03-30百时美施贵宝公司Nalidinone compounds as T cell activators
KR102804324B1 (en)2018-06-272025-05-08브리스톨-마이어스 스큅 컴퍼니 Naphthyridinone compounds useful as T cell activators
AU2019291794B2 (en)*2018-06-272022-06-16Bristol-Myers Squibb CompanySubstituted naphthyridinone compounds useful as T cell activators
WO2020006016A1 (en)*2018-06-272020-01-02Bristol-Myers Squibb CompanyNaphthyridinone compounds useful as t cell activators
KR102767739B1 (en)2018-06-272025-02-12브리스톨-마이어스 스큅 컴퍼니 Substituted naphthyridinone compounds useful as T cell activators
US11713316B2 (en)2018-06-272023-08-01Bristol-Myers Squibb CompanySubstituted naphthyridinone compounds useful as T cell activators
US11866430B2 (en)2018-06-272024-01-09Bristol-Myers Squibb CompanyNaphthyridinone compounds useful as T cell activators
US11584747B2 (en)2019-08-282023-02-21Bristol-Myers Squibb CompanySubstituted pyridopyrimidinonyl compounds useful as T cell activators
US11964973B2 (en)2019-12-232024-04-23Bristol-Myers Squibb CompanySubstituted bicyclic compounds useful as T cell activators
US11807638B2 (en)2020-10-052023-11-07Enliven Inc.5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases
US11767321B2 (en)2020-10-052023-09-26Enliven Inc.5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases
US12240846B2 (en)2020-10-052025-03-04Enliven Inc.5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases
WO2022093817A1 (en)*2020-10-262022-05-05Yale UniversityMacrophage migration inhibitory factor inhibitors, and methods of making and using same

Also Published As

Publication numberPublication date
WO2005021546A1 (en)2005-03-10
JP2007503388A (en)2007-02-22
PE20051112A1 (en)2006-02-03
AR045471A1 (en)2005-10-26
BRPI0413695A (en)2006-10-24
CN1839133A (en)2006-09-27
CA2531506A1 (en)2005-03-10
EP1656376A1 (en)2006-05-17
TW200524928A (en)2005-08-01
AU2004268941A1 (en)2005-03-10
MXJL06000006A (en)2006-05-04
UY28483A1 (en)2005-03-31
US20070191388A1 (en)2007-08-16
US7361760B2 (en)2008-04-22

Similar Documents

PublicationPublication DateTitle
US7361760B2 (en)Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
US7312220B2 (en)Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US7238809B2 (en)Process for the preparation of inhibitors of macrophage migration inhibitory factor

Legal Events

DateCodeTitleDescription
ASAssignment

Owner name:AVANIR PHARMACEUTICALS, INC., CALIFORNIA

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SIRCAR, JAGADISH;KUMAR K. C., SUNIL;YING, WENBIN;AND OTHERS;REEL/FRAME:015581/0232

Effective date:20050111

STCBInformation on status: application discontinuation

Free format text:ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION
[8]ページ先頭
©2009-2025 Movatter.jp